Assessing Corvus Pharmaceuticals (CRVS) Valuation After Rapid Multi-Year Share Price Gains [Yahoo! Finance]
Corvus Pharmaceuticals, Inc. (CRVS)
Last corvus pharmaceuticals, inc. earnings: 4/30 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
corvuspharma.com
Company Research
Source: Yahoo! Finance
Corvus Pharmaceuticals (CRVS) has recently drawn attention after a 91.3% gain over the past 3 months, alongside a 255.8% 1 year total return. This has prompted investors to reassess its risk and potential. See our latest analysis for Corvus Pharmaceuticals. Those moves sit alongside a 118.7% year to date share price return and a very large 3 year total shareholder return. The recent 30 day share price decline of 18.2% suggests some of that momentum has cooled near the current US$16.01 level. If Corvus has put high growth biotech on your radar, it could be worth seeing what else is out there via our screener of 34 healthcare AI stocks as potential next ideas. So with Corvus still loss making, yet trading at US$16.01 against an analyst target of US$35.00 and a very large 3 year total return, are you looking at a genuine opportunity or a market that has already priced in future growth? Most Popular Narrative: 54.3% Undervalued The most followed narrative currently points to
Show less
Read more
Impact Snapshot
Event Time:
CRVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRVS alerts
High impacting Corvus Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
CRVS
News
- Corvus Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]Yahoo! Finance
- Corvus Pharmaceuticals (CRVS) had its "outperform" rating reaffirmed by Oppenheimer Holdings, Inc.. They now have a $33.00 price target on the stock, up from $32.00.MarketBeat
- Corvus Pharmaceuticals Inc (CRVS) Q4 2025 Earnings Call Highlights: Strategic Advances Amid ... [Yahoo! Finance]Yahoo! Finance
- Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]Yahoo! Finance
- Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewswire
CRVS
Earnings
- 3/12/26 - Miss
CRVS
Sec Filings
- 3/13/26 - Form 8-K
- 3/13/26 - Form 424B5
- 3/13/26 - Form S-3ASR
- CRVS's page on the SEC website